Bank of The West cut its stake in shares of CIGNA Co. (NYSE:CI) by 12.3% during the 4th quarter, Holdings Channel reports. The firm owned 10,146 shares of the health services provider’s stock after selling 1,428 shares during the period. Bank of The West’s holdings in CIGNA were worth $2,061,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in CI. Argent Capital Management LLC boosted its position in CIGNA by 2.0% during the 2nd quarter. Argent Capital Management LLC now owns 2,613 shares of the health services provider’s stock worth $437,000 after buying an additional 50 shares during the period. Eqis Capital Management Inc. boosted its position in CIGNA by 3.1% during the 3rd quarter. Eqis Capital Management Inc. now owns 8,949 shares of the health services provider’s stock worth $1,673,000 after buying an additional 267 shares during the period. Commerzbank Aktiengesellschaft FI boosted its position in CIGNA by 19.5% during the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 1,667 shares of the health services provider’s stock worth $339,000 after buying an additional 272 shares during the period. Comerica Bank boosted its position in CIGNA by 0.4% during the 3rd quarter. Comerica Bank now owns 62,611 shares of the health services provider’s stock worth $12,379,000 after buying an additional 274 shares during the period. Finally, Investec Asset Management PTY Ltd boosted its position in CIGNA by 3.4% during the 3rd quarter. Investec Asset Management PTY Ltd now owns 8,865 shares of the health services provider’s stock worth $1,645,000 after buying an additional 290 shares during the period. 88.04% of the stock is currently owned by institutional investors.

CIGNA Co. (NYSE CI) opened at $195.44 on Thursday. The stock has a market cap of $47,917.56, a P/E ratio of 22.39, a PEG ratio of 1.18 and a beta of 0.45. CIGNA Co. has a 1 year low of $141.93 and a 1 year high of $227.13. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.37 and a quick ratio of 0.39.

CIGNA (NYSE:CI) last issued its quarterly earnings results on Thursday, February 1st. The health services provider reported $1.94 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.07. The firm had revenue of $10.53 billion for the quarter, compared to the consensus estimate of $10.28 billion. CIGNA had a net margin of 5.38% and a return on equity of 18.84%. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.87 EPS. equities research analysts forecast that CIGNA Co. will post 12.9 earnings per share for the current fiscal year.

In related news, insider Michael W. Triplett sold 10,417 shares of the business’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $197.77, for a total transaction of $2,060,170.09. Following the transaction, the insider now owns 32,347 shares in the company, valued at approximately $6,397,266.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director William D. Zollars sold 212 shares of the business’s stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $205.68, for a total transaction of $43,604.16. Following the transaction, the director now owns 13,500 shares in the company, valued at approximately $2,776,680. The disclosure for this sale can be found here. Insiders sold a total of 75,080 shares of company stock worth $15,390,073 in the last 90 days. Corporate insiders own 1.30% of the company’s stock.

Several equities research analysts recently commented on CI shares. Jefferies Group lifted their target price on shares of CIGNA from $221.00 to $231.00 and gave the stock a “buy” rating in a research report on Friday, November 3rd. Zacks Investment Research upgraded shares of CIGNA from a “hold” rating to a “buy” rating and set a $231.00 target price on the stock in a research report on Friday, December 22nd. Citigroup lifted their target price on shares of CIGNA from $198.00 to $231.00 and gave the stock a “buy” rating in a research report on Friday, November 3rd. ValuEngine upgraded shares of CIGNA from a “hold” rating to a “buy” rating in a research report on Sunday, December 31st. Finally, BMO Capital Markets started coverage on shares of CIGNA in a research report on Monday, October 16th. They set a “market perform” rating and a $210.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. CIGNA currently has a consensus rating of “Buy” and a consensus price target of $210.12.

COPYRIGHT VIOLATION WARNING: “Bank of The West Decreases Position in CIGNA Co. (CI)” was first published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.dailypolitical.com/2018/02/08/bank-of-the-west-decreases-position-in-cigna-co-ci.html.

About CIGNA

Cigna Corporation (Cigna), together with its subsidiaries, is a health services company. The Company offers medical, dental, disability, life and accident insurance and related products and services. The Company’s segments include Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations and Corporate.

Want to see what other hedge funds are holding CI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CIGNA Co. (NYSE:CI).

Institutional Ownership by Quarter for CIGNA (NYSE:CI)

Receive News & Ratings for CIGNA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CIGNA and related companies with MarketBeat.com's FREE daily email newsletter.